EDGEMOND JAMES sold $529K of UTHR
EDGEMOND JAMES (CFO AND TREASURER) sold 934 shares of UNITED THERAPEUTICS Corp (UTHR) at $566.87 ($0.53M total) on 2026-05-28 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The key datapoint is the CFO/treasurer’s open-market sale of 934 shares at ~$566.87, explicitly under a pre-arranged Rule 10b5-1 plan.
Market read
Traders may briefly reassess positioning in UTHR on insider-selling headlines, but 10b5-1 typically limits interpretive value.
What to watch
The sale size ($529k) is modest relative to a large-cap biotech; without additional context (e.g., multiple concurrent sales), signal is likely weak.
Background
The article is an SEC Form 4 insider transaction disclosure for United Therapeutics (UTHR).
Ticker impact
SEC Form 4 shows UTHR CFO/treasurer Edgemond James sold 934 shares in an open-market transaction under a 10b5-1 plan.
Limited near-term impact; any reaction is likely muted and short-lived.
The filing is a routine insider transaction with stated 10b5-1 pre-arrangement, reducing inference about new negative information.
Market effects
No direct sector read-through; this is company-specific insider transaction disclosure.
None expected beyond UTHR-specific sentiment.
None expected.
Counterpoint
Even with 10b5-1, repeated insider selling can coincide with periods of weaker outlook; traders may still monitor for clustering of sales.
Key entities
- issuerUnited Therapeutics Corp
Subject of the insider transaction disclosure; CFO/treasurer sold shares via open-market sale under 10b5-1.
- insiderEdgemond James
CFO and treasurer who executed the sale disclosed on Form 4.
